Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Novavax (NVAX) Notes Payables (2016 - 2022)

Historic Notes Payables for Novavax (NVAX) over the last 9 years, with Q4 2022 value amounting to $324.9 million.

Novavax's Notes Payables changed N/A to $324.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $324.9 million, marking a year-over-year change of. This contributed to the annual value of $324.9 million for FY2022, which is N/A changed from last year.
Novavax's Notes Payables amounted to $324.9 million in Q4 2022.
In the past 5 years, Novavax's Notes Payables registered a high of $324.9 million during Q4 2022, and its lowest value of $323.8 million during Q1 2022.